XRP price is further depressing into a loss-driven phase as selling picks up speed in both the spot and derivatives markets.  XRP was trading at $1.44 at press XRP price is further depressing into a loss-driven phase as selling picks up speed in both the spot and derivatives markets.  XRP was trading at $1.44 at press

XRP price enters stop-loss phase after SOPR breaks below 1.0 for the first time since 2022

2026/02/10 14:45
4 min read

XRP price is further depressing into a loss-driven phase as selling picks up speed in both the spot and derivatives markets. 

Summary
  • XRP has entered a stop-loss phase as on-chain profitability turns negative.
  • Recent selling pressure is driven mainly by smaller holders, not whales.
  • Technical structure continues to favor downside despite rising trading activity.

XRP was trading at $1.44 at press time, down about 1% in the last day. The price has dropped by roughly 10% in the past week, 30% in the last month, and over 40% in the last year. Since its peak of $3.65 in July 2025, XRP has experienced a significant decline, losing nearly 60% of its value.

Despite the price slide, activity has picked up. Spot trading volume climbed 22% in the last 24 hours to $3.45 billion, suggesting active re-positioning rather than quiet drift. Derivatives data paints a more cautious picture.

According to CoinGlass data, XRP (XRP) futures volume rose 12% to $5.66 billion, while open interest slipped slightly by 0.17% to $2.50 billion, pointing to traders closing exposure rather than adding fresh leverage.

On-chain data points to stop-loss driven selling

On-chain signals suggest the recent move lower is being driven less by whales and more by holders exiting at a loss. In a Feb. 9 X post, Glassnode noted that XRP has fallen below the aggregate cost basis of its holders, pushing the market into what they described as a “stop-loss phase.”

https://twitter.com/glassnode/status/2020896475488641261?s=46&t=nznXkss3debX8JIhNzHmzw

The firm noted that the 7-day EMA of Spent Output Profit Ratio has dropped from 1.16 in July 2025 to 0.96, its first sustained move below 1.0 since 2022. When SOPR falls under this level, it means coins are being sold at a loss on average.

On-chain profitability has flipped negative, and realized losses are now outweighing realized gains. Glassnode compared the current setup to the September 2021 to May 2022 period, when XRP spent months consolidating after SOPR slipped below 1.0.

Data from CryptoQuant adds another layer. Analyst PelinayPA noted that whale-to-exchange flow remains near historical lows, even as price has dropped to around $1.42–$1.45.

During the July 2025 rally, whale selling surged near the top. That pattern has not appeared this time. Rather, smaller holders have been the main source of selling pressure recently, and big players seem to be holding off on distributing until prices have increased.

This type of arrangement has historically resulted in sideways or slightly lower price action before short upward spikes draw whale selling.

XRP price technical analysis

The daily chart continues to form lower highs, leaving the broader downside bias in place despite short-lived rebound attempts. Both the 50-day and 100-day moving averages, which have begun to decline and are currently serving as overhead resistance, are limiting the upside momentum.

XRP price enters stop-loss phase after SOPR breaks below 1.0 for the first time since 2022 - 1

After multiple unsuccessful attempts to stay above the mid-band, the price has been pushed toward the lower Bollinger Band, indicating that volatility is settling to the downside rather than creating a stable range.

There is currently no confirmed bullish divergence, and the daily relative strength index is still below neutral, indicating weak momentum. 

Volume behavior lends more credence to this view. Although there hasn’t been a noticeable capitulation spike, increased selling has been observed on down days, suggesting steady stop-loss activity as opposed to panic selling. 

Previously a strong support area, the $1.45–$1.50 range is now being retested with a notably weaker buyer response. Attempts to reclaim previous breakdown levels were quickly rejected, indicating strong overhead supply.

If selling pressure remains high, the price could move toward the $1.35–$1.30 support zone, where buyers had stepped in during late 2024. A daily close below $1.30 would make a deeper decline toward $1.20 more likely, a level where longer-term demand has previously been seen.

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0005411
$0.0005411$0.0005411
+15.54%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26